BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8617331)

  • 1. Plasmodium yoelii: the role of the individual epidermal growth factor-like domains of the merozoite surface protein-1 in protection from malaria.
    Calvo PA; Daly TM; Long CA
    Exp Parasitol; 1996 Jan; 82(1):54-64. PubMed ID: 8617331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
    Rotman HL; Daly TM; Long CA
    Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.
    Daly TM; Long CA
    J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model.
    Rotman HL; Daly TM; Clynes R; Long CA
    J Immunol; 1998 Aug; 161(4):1908-12. PubMed ID: 9712060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.
    Kang Y; Calvo PA; Daly TM; Long CA
    J Immunol; 1998 Oct; 161(8):4211-9. PubMed ID: 9780195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
    Wang L; Goschnick MW; Coppel RL
    Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants.
    Wang L; Webster DE; Campbell AE; Dry IB; Wesselingh SL; Coppel RL
    Int J Parasitol; 2008 Jan; 38(1):103-10. PubMed ID: 17681344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.
    Wang R; Charoenvit Y; Corradin G; Porrozzi R; Hunter RL; Glenn G; Alving CR; Church P; Hoffman SL
    J Immunol; 1995 Mar; 154(6):2784-93. PubMed ID: 7876549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
    Shi Q; Lynch MM; Romero M; Burns JM
    Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii.
    Burns JM; Majarian WR; Young JF; Daly TM; Long CA
    J Immunol; 1989 Oct; 143(8):2670-6. PubMed ID: 2477452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.
    Hirunpetcharat C; Vukovic P; Liu XQ; Kaslow DC; Miller LH; Good MF
    J Immunol; 1999 Jun; 162(12):7309-14. PubMed ID: 10358180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against malaria is conferred by passive transferring rabbit F(ab)(2)' antibody fragments, induced by Plasmodium falciparum MSP-1 site-directed designed pseudopeptide-BSA conjugates assessed in a rodent model.
    Lozano JM; Lesmes LP; Gallego GM; Patarroyo ME
    Mol Immunol; 2011 Jan; 48(4):657-69. PubMed ID: 21131051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
    RĂ©nia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
    Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
    Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
    J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective immune mechanisms induced by cellular vaccine made of the erythrocytic Plasmodium yoelii].
    Yuan J; Xu B; Liu BF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):47-51. PubMed ID: 15052774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites.
    Charoenvit Y; Mellouk S; Cole C; Bechara R; Leef MF; Sedegah M; Yuan LF; Robey FA; Beaudoin RL; Hoffman SL
    J Immunol; 1991 Feb; 146(3):1020-5. PubMed ID: 1988490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1.
    James S; Moehle K; Renard A; Mueller MS; Vogel D; Zurbriggen R; Pluschke G; Robinson JA
    Chembiochem; 2006 Dec; 7(12):1943-50. PubMed ID: 17068840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
    Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL
    J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.
    O'Donnell RA; Saul A; Cowman AF; Crabb BS
    Nat Med; 2000 Jan; 6(1):91-5. PubMed ID: 10613831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.